We are live on ! Find out more
BFM

Boothbay Fund Management Portfolio holdings

AUM $7.71B
1-Year Est. Return 106.31%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+106.31%
3 Year Est. Return
+266.76%
5 Year Est. Return
+310.53%
10 Year Est. Return
+1,580.35%
AUM
$4.56B
AUM Growth
-$316M
Cap. Flow
-$742M
Cap. Flow %
-16.27%
Top 10 Hldgs %
15.49%
Holding
2,634
New
531
Increased
353
Reduced
471
Closed
900

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$26.9M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$24.7M
3
AMZN icon
Amazon
AMZN
+$22.4M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$21.7M
5
MDY icon
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
+$18M

Top Sells

Rank Stock Value
1
CVII
Churchill Capital Corp VII Class A Common Stock
CVII
+$23.1M
2
WMT icon
Walmart Inc
WMT
+$17.7M
3
BURL icon
Burlington
BURL
+$12.7M
4
ALCE
Alternus Clean Energy Inc
ALCE
+$12.1M
5
GILD icon
Gilead Sciences
GILD
+$11.7M

Sector Composition

Rank Sector Weight
1 Healthcare 9.99%
2 Technology 9.63%
3 Financials 7.8%
4 Industrials 6.22%
5 Consumer Discretionary 5.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FEXDR
1601
DELISTED
Fintech Ecosystem Development Corp. Right
FEXDR
$47.4K ﹤0.01%
400,000
– –
CETUR
1602
DELISTED
Cetus Capital Acquisition Corp. Right
CETUR
$46.7K ﹤0.01%
203,040
– –
ICCM icon
1603
IceCure Medical
ICCM
$9.9M
$46.4K ﹤0.01%
1,333
– –
VHAQ.RT
1604
DELISTED
Viveon Health Acquisition Corp. Rights, each exchangeable into one-twentieth of a share of Common Stock
VHAQ.RT
$46K ﹤0.01%
802,000
– –
TARA icon
1605
Protara Therapeutics
TARA
$220M
$45.1K ﹤0.01%
18,864
– –
PYPD icon
1606
PolyPid
PYPD
$82.3M
$44.5K ﹤0.01%
4,063
-34
-0.8% -$409
ASCBR
1607
DELISTED
A SPAC II Acquisition Corp. Right
ASCBR
$42.8K ﹤0.01%
450,000
– –
IGTAR
1608
DELISTED
Inception Growth Acquisition Limited Rights
IGTAR
$42.5K ﹤0.01%
250,000
– –
CLOER
1609
DELISTED
Clover Leaf Capital Corp. Rights
CLOER
$42.1K ﹤0.01%
347,800
– –
MARXR
1610
DELISTED
Mars Acquisition Corp. Rights
MARXR
$42.1K ﹤0.01%
168,396
– –
WTMAR
1611
DELISTED
Welsbach Technology Metals Acquisition Corp. one right to receive 1/10th of a share of common stock
WTMAR
$42K ﹤0.01%
621,600
– –
WINVR
1612
DELISTED
WinVest Acquisition Corp. Right
WINVR
$41.3K ﹤0.01%
590,000
– –
ANEB
1613
DELISTED
Anebulo Pharmaceuticals
ANEB
$40.7K ﹤0.01%
17,319
– –
RSI icon
1614
Rush Street Interactive
RSI
$2.77B
$40.5K ﹤0.01%
+12,995
New +$40.1K
ATAKR
1615
DELISTED
Aurora Technology Acquisition Corp. Rights
ATAKR
$40.2K ﹤0.01%
335,000
– –
BCLI
1616
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$39.3K ﹤0.01%
1,273
– –
SURF
1617
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$39.1K ﹤0.01%
+45,000
New +$32.1K
AIBBR
1618
DELISTED
AIB Acquisition Corp Right
AIBBR
$36.8K ﹤0.01%
350,000
– –
CLRCR
1619
DELISTED
ClimateRock Right
CLRCR
$36K ﹤0.01%
300,000
– –
CMMB
1620
Chemomab Therapeutics
CMMB
$11.4M
$34.9K ﹤0.01%
6,632
– –
RFACR
1621
DELISTED
RF Acquisition Corp. Rights
RFACR
$34.2K ﹤0.01%
400,000
– –
TMTCR
1622
DELISTED
TMT Acquisition Corp Rights
TMTCR
$33.6K ﹤0.01%
+69,280
New +$19.1K
CREXW
1623
DELISTED
Creative Realities, Inc. Warrant
CREXW
$33.3K ﹤0.01%
10,906
– –
MRSN
1624
DELISTED
Mersana Therapeutics
MRSN
$33K ﹤0.01%
+401
New +$58.7K
RLMD icon
1625
Relmada Therapeutics
RLMD
$557M
$31.5K ﹤0.01%
12,792
– –
63 64
65
66 67

Similar funds

MAM
Magellan Asset Management Sydney, Australia $7.71B AUM 11.08% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
WRCM
Whale Rock Capital Management Boston, Massachusetts $7.74B AUM 180.85% 1-Year Est. Return
IMCOOI
Investment Management Corp of Ontario (IMCO) Toronto, Canada $7.76B AUM 99.29% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return
CCM
Carronade Capital Management Darien, Connecticut $7.65B AUM 80.26% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
PGFC
Peapack-Gladstone Financial Corp Bedminster, New Jersey $7.82B AUM 21.06% 1-Year Est. Return

Boothbay Fund Management's Q2 2023 Portfolio in Review

As of Q2 2023, Boothbay Fund Management held 2,634 positions worth $4.56B, down 6.5% from $4.87B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Boothbay Fund Management withdrew a net $742M in Q2 2023, closing 900 positions and reducing 471 holdings. Its most notable exit was Alternus Clean Energy Inc, an estimated $12.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 10% a quarter earlier, followed by Technology and Financials.

Against the trend, Boothbay Fund Management opened a new position in Indivior Pharmaceuticals worth $21.9M.

  • Boothbay Fund Management's largest Q2 2023 buy was Indivior Pharmaceuticals: 946,208 shares worth $21.9M.
  • Boothbay Fund Management added most to State Street SPDR S&P 500 ETF Trust in Q2 2023, an estimated $26.9M increase.
  • Boothbay Fund Management's biggest Q2 2023 reduction was Churchill Capital Corp VII Class A Common Stock, cutting an estimated $23.1M.
  • Boothbay Fund Management fully exited Alternus Clean Energy Inc in Q2 2023, selling an estimated $12.1M.
  • Boothbay Fund Management's ten largest holdings make up 15% of its $4.56B portfolio in Q2 2023.
  • Boothbay Fund Management opened 531 new positions and closed 900 in Q2 2023.
  • Boothbay Fund Management's portfolio value fell 6.5% quarter-over-quarter to $4.56B.

Based on Boothbay Fund Management's 13F filing for Q2 2023, filed 14 Aug 2023.